Clay Siegall is a co-founder of Seattle genetics which started in 1998. Clay is the CEO and President. He also serves as the Chairman of the Board of Directors. Dr. Clay Siegall is a polished scientist with a focus on specific cancer therapies. He was inspired to start the Seattle Genetics outfit by the urge to promote innovation in the field of science. He intended to conduct in-depth research that seeks to understand the cancer pandemic and other conditions that trouble patients, including developing drugs based on best research and science practice.
Dr. Clay Siegall is Compassionate with Patients
He has always had a deep sensitivity to the condition of patients. He was inspired by patients to start a science and research center so as to find a way to arrive at faster solutions to patient problems across the spectrum of diseases. Seattle Genetics is now a trendsetter in the drug development research field. The research firm is a global leader in developing anti-drug conjugates, also commonly referred to as ADCs. The company managed to convince the FDA to grant it its first approval of the ADC product coded ADCETRIS. The Center collaborates with Takeda Takeda Pharmaceutical Company and has succeeded in launching the conjugate on a global scale. It has secured approval in over 65 countries across the globe. The research, and drug development firm has already developed a diverse supply line for the supply of ADC for treating cancer.
Creating Awareness about ADC and Distributing It to Reach the Cancer Patients
Dr. Clay Siegall’s company, Seattle Genetics has got into several licensing arrangements as a strategy to promote the ADC technology. Some of the firms it has engaged include Gentech, GlaxoSmithKline, AbbVie, and Pfizer. So far, the companies have collected revenue exceeding $350 million. Seattle Genetics says that there are over 20 ADCs under clinical development process using the Seattle genetics technology.
About Dr. Clay Siegall
He is a co-founder of Seattle Genetics. He holds a Ph.D. in Science Research. Dr. Clay Siegall is the current Chief Executive officer of the company and also serves as both its president and the Chairman of the Board. Seattle Genetics is a leading cancer research company that has produced several working therapies for cancer, including ADCETRIS.